HC Wainwright Issues Positive Forecast for SXTP Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Research analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of 60 Degrees Pharmaceuticals in a research note issued to investors on Monday, August 17th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings per share of ($0.61) for the quarter, up from their prior estimate of ($0.64). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($3.30) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($3.16) EPS.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16). The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.20 million.

A number of other research analysts also recently issued reports on SXTP. Ascendiant Capital Markets lowered their price target on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating on the stock in a report on Friday, May 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $13.85.

60 Degrees Pharmaceuticals Trading Up 3.7%

SXTP stock opened at $1.12 on Wednesday. The stock’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.94. 60 Degrees Pharmaceuticals has a 12-month low of $1.02 and a 12-month high of $8.62. The stock has a market capitalization of $2.98 million, a PE ratio of -0.23 and a beta of 2.54.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.